Long acting beta2 agonists: are they safe?
Wijesiriwardena
Bandula
B
Colombo South Teaching Hospital, Kalubowila, Sri Lanka. bandulawije@lycos.com
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D006801:Humans; D011358:Product Surveillance, Postmarketing; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects*; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D018343:Receptors, Adrenergic, beta-2